Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking Cells
May 21, 2024 08:00 ET
|
Morphic Therapeutic
in vivo video presented at DDW 2024 show small molecule α4β7 inhibition rapidly increases rolling velocity & flux of B cells similar to antibodies
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
May 20, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Four device performance studies demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions.
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
May 08, 2024 02:30 ET
|
Abivax
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST –...
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
April 04, 2024 08:00 ET
|
Biora Therapeutics, Inc.
All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed
Abivax reports 2023 financial results and operational update
April 02, 2024 02:30 ET
|
Abivax
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and...
Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease
March 20, 2024 20:05 ET
|
Sosei Group Corporation
HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei...
Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
March 20, 2024 20:01 ET
|
Sosei Group Corporation
GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesReturn of rights follows change in immunology research strategy...
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
February 26, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Data from SAD cohort expected to be shared during March corporate update; MAD cohorts to begin dosing in March.
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
February 08, 2024 08:00 ET
|
Biora Therapeutics, Inc.
Dr. Ariella Kelman to participate in panel titled "The Next Evolutionary Steps in Addressing IBD" on Feb 28, 2024.
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
February 02, 2024 02:30 ET
|
Abivax
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease Obefazimod Crohn’s Disease (CD) IND filed with the FDA in December...